Maze Therapeutics (NASDAQ:MAZE) Trading Up 6.4% – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares traded up 6.4% during mid-day trading on Monday . The stock traded as high as $12.88 and last traded at $12.77. 27,430 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 270,449 shares. The stock had previously closed at $12.00.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Guggenheim initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price objective for the company. Leerink Partners started coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 target price for the company. Leerink Partnrs raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Stock Down 1.8 %

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.